Hepatic Rupture as the Initial Presentation of an
EGFR mutations
case report
metastatic hepatic rupture
non-small cell lung carcinoma
tyrosine kinase inhibitor
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
16
12
2021
accepted:
07
03
2022
entrez:
18
4
2022
pubmed:
19
4
2022
medline:
19
4
2022
Statut:
epublish
Résumé
Hepatic rupture is a rare complication of solid tumor malignancies, notably in lung adenocarcinomas, and carries an extremely poor overall prognosis. Epidermal growth factor receptor (EGFR) mutations in lung adenocarcinoma predict benefit with tyrosine kinase inhibitors (TKIs). This case report describes a female patient who presented with a metastatic hepatic rupture and was subsequently diagnosed with
Identifiants
pubmed: 35433405
doi: 10.3389/fonc.2022.837630
pmc: PMC9005950
doi:
Types de publication
Case Reports
Langues
eng
Pagination
837630Informations de copyright
Copyright © 2022 Mirallas, Bosch-Schips, Pardo, Aubanell, Salcedo-Allende, Callejo, Iranzo, Tabernero and Felip.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
N Engl J Med. 2009 Sep 3;361(10):947-57
pubmed: 19692680
Arch Surg. 1999 Oct;134(10):1103-7
pubmed: 10522855
HPB (Oxford). 2015 Oct;17(10):872-80
pubmed: 26252245
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv192-iv237
pubmed: 30285222
Oncotarget. 2016 Nov 29;7(48):78985-78993
pubmed: 27738317
Lancet Oncol. 2012 Mar;13(3):239-46
pubmed: 22285168
Intern Med. 2005 Jan;44(1):50-4
pubmed: 15704663
Lancet Oncol. 2016 May;17(5):577-89
pubmed: 27083334
J Clin Oncol. 2009 Mar 20;27(9):1394-400
pubmed: 19224850
Anticancer Res. 2013 Aug;33(8):3279-84
pubmed: 23898092
Dig Dis Sci. 1992 Jan;37(1):153-4
pubmed: 1728523
Lancet Oncol. 2011 Aug;12(8):735-42
pubmed: 21783417